Valproic acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing  Valproic acid, Epicatechin and Matrine (VAEM)  inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 20/December/2018, 11.08 pm